Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
|
Press Release - Concert Pharmaceuticals, Inc. (Private) |
|
|
“The vision behind Concert is to take a different tack at drug discovery that would enable the creation of new chemical entities (NCEs), first-and best-in-class new medicines, in a way that substantially reduces the risks associated with current drug development approaches and increases the likelihood of their successful commercial development.” - Roger Tung, Ph.D. (Interview published February 19, 2009) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
Sept. 3, 2009 11:30 UTC
Concert Pharmaceuticals to Present at the Thomas Weisel Partners 2009 Healthcare Conference on September 10, 2009
LEXINGTON, Mass.--(BUSINESS
WIRE)--
Concert Pharmaceuticals, Inc. announced
today that Roger Tung, Ph.D., President and
Chief
Executive Officer of Concert, will present at
the Thomas Weisel Partners 2009 Healthcare
Conference
on Thursday, September 10, 2009 at 10:55 a.m. Eastern
Time. The conference will be held
September 9-11, 2009 at the Four Seasons
Hotel in Boston, Massachusetts.
About Concert Concert Pharmaceuticals is a clinical stage biotechnology company focused on the application of deuterium chemistry to create novel small molecule drugs. Concert’s approach leverages known activity and safety of existing drugs to reduce time, risk and expense of drug research and development. The Company has a broad research pipeline encompassing many therapeutic areas including infectious disease and renal disease, among others. Its lead development candidate is the HIV protease inhibitor CTP-518. In 2009, Concert entered into a potential $1 billion collaboration with GlaxoSmithKline to develop certain deuterium-containing medicines. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit www.concertpharma.com. CoNCERT and CoNCERT Pharmaceuticals are trademarks of Concert Pharmaceuticals, Inc. Contacts
Concert Pharmaceuticals, Inc.
Justine E. Koenigsberg, 781-674-5284 Senior Director, Corporate Communications and Investor Relations Source: Concert Pharmaceuticals, Inc.
|
|
